Changes to This Summary (05/20/2011)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Staging and Diagnostic Evaluation

Added Molnar et al. as reference 16.

Treatment Approach for Children and Adolescents with Hodgkin Lymphoma

Revised text to state that in an effort to decrease risk for male infertility, etoposide has been substituted for procarbazine in the initial courses of therapy in studies of the German pediatric Hodgkin lymphoma group and dacarbazine for procarbazine in subsequent courses; in the GPOH-HD-2002 study, the 5-year overall survival was 97% and event-free survival was 89%, with no difference in outcome between boys and girls (cited Mauz-Körholz et al. as reference 11 and level of evidence 2A).

Added text to Table 1 to state that OEPA +/- COPDAC is another chemotherapy regimen for males.

Revised text to state that OPPA/OEPA × 2; COPP × 2 (girls) or COPDAC x 2 (boys), plus LD-IFRT are accepted treatment strategies for newly diagnosed children and adolescent patients with intermediate-risk disease.

Revised text to state that OPPA/OEPA × 2; COPP × 4 (girls) or COPDAC x 4 (boys), plus LD-IFRT are accepted treatment strategies for newly diagnosed children and adolescent patients with high-risk disease.

Late Effects from Childhood/Adolescent Hodgkin Lymphoma Therapy

Added text to state that female survivors of Hodgkin lymphoma who develop breast cancer have a seven-fold increase in rate of death, even when adjusted for stage, compared with patients who develop breast cancer de novo; they also have a two-fold increase in the rate of death from cardiac disease (cited Milano et al. as reference 66 and level of evidence 3iDi).